27516217|t|Chronic exposure to haloperidol and olanzapine leads to common and divergent shape changes in the rat hippocampus in the absence of grey-matter volume loss
27516217|a|One of the most consistently reported brain abnormalities in schizophrenia (SCZ) is decreased volume and shape deformation of the hippocampus. However, the potential contribution of chronic antipsychotic medication exposure to these phenomena remains unclear. We examined the effect of chronic exposure (8 weeks) to clinically relevant doses of either haloperidol (HAL) or olanzapine (OLZ) on adult rat hippocampal volume and shape using ex vivo structural MRI with the brain retained inside the cranium to prevent distortions due to dissection, followed by tensor-based morphometry (TBM) and elastic surface-based shape deformation analysis. The volume of the hippocampus was also measured post-mortem from brain tissue sections in each group. Chronic exposure to either HAL or OLZ had no effect on the volume of the hippocampus, even at exploratory thresholds, which was confirmed post-mortem. In contrast, shape deformation analysis revealed that chronic HAL and OLZ exposure lead to both common and divergent shape deformations (q = 0.05, FDR-corrected) in the rat hippocampus. In particular, in the dorsal hippocampus, HAL exposure led to inward shape deformation, whereas OLZ exposure led to outward shape deformation. Interestingly, outward shape deformations that were common to both drugs occurred in the ventral hippocampus. These effects remained significant after controlling for hippocampal volume suggesting true shape changes. Chronic exposure to either HAL or OLZ leads to both common and divergent effects on rat hippocampal shape in the absence of volume change. The implications of these findings for the clinic are discussed.
27516217	0	19	Chronic exposure to	T033	C0743284
27516217	20	31	haloperidol	T109,T121	C0018546
27516217	36	46	olanzapine	T109,T121	C0171023
27516217	77	90	shape changes	T033	C1562006
27516217	98	101	rat	T015	C0034693
27516217	102	113	hippocampus	T023	C0019564
27516217	132	143	grey-matter	T024	C0018220
27516217	144	155	volume loss	T169	C0205245
27516217	194	213	brain abnormalities	T190	C4021085
27516217	217	230	schizophrenia	T048	C0036341
27516217	232	235	SCZ	T048	C0036341
27516217	250	278	volume and shape deformation	T033	C1562006
27516217	286	297	hippocampus	T023	C0019564
27516217	338	370	chronic antipsychotic medication	T121	C0040615
27516217	371	379	exposure	T033	C0743284
27516217	442	458	chronic exposure	T033	C0743284
27516217	483	497	relevant doses	T081	C0178602
27516217	508	519	haloperidol	T109,T121	C0018546
27516217	521	524	HAL	T109,T121	C0018546
27516217	529	539	olanzapine	T109,T121	C0171023
27516217	541	544	OLZ	T109,T121	C0171023
27516217	555	558	rat	T015	C0034693
27516217	559	570	hippocampal	T029	C3496509
27516217	571	587	volume and shape	T033	C0243095
27516217	594	601	ex vivo	T169	C2348480
27516217	602	616	structural MRI	T060	C0024485
27516217	626	659	brain retained inside the cranium	T023	C0037303
27516217	671	682	distortions	T190	C0332482
27516217	690	700	dissection	T061	C0012737
27516217	714	738	tensor-based morphometry	T059	C0200760
27516217	740	743	TBM	T059	C0200760
27516217	749	797	elastic surface-based shape deformation analysis	T062	C0936012
27516217	817	828	hippocampus	T023	C0019564
27516217	847	858	post-mortem	T060	C0004398
27516217	864	876	brain tissue	T023	C0459385
27516217	901	917	Chronic exposure	T033	C0743284
27516217	928	931	HAL	T109,T121	C0018546
27516217	935	938	OLZ	T109,T121	C0171023
27516217	974	985	hippocampus	T023	C0019564
27516217	995	1017	exploratory thresholds	T060	C0430009
27516217	1039	1050	post-mortem	T060	C0004398
27516217	1065	1091	shape deformation analysis	T062	C0936012
27516217	1114	1117	HAL	T109,T121	C0018546
27516217	1122	1125	OLZ	T109,T121	C0171023
27516217	1126	1134	exposure	T033	C0743284
27516217	1159	1187	divergent shape deformations	T033	C1562006
27516217	1221	1224	rat	T015	C0034693
27516217	1225	1236	hippocampus	T023	C0019564
27516217	1260	1278	dorsal hippocampus	T023	C0019564
27516217	1280	1283	HAL	T109,T121	C0018546
27516217	1284	1292	exposure	T033	C0743284
27516217	1300	1324	inward shape deformation	T033	C1562006
27516217	1334	1337	OLZ	T109,T121	C0171023
27516217	1338	1346	exposure	T033	C0743284
27516217	1354	1379	outward shape deformation	T033	C1562006
27516217	1396	1422	outward shape deformations	T033	C1562006
27516217	1448	1453	drugs	T121	C0013227
27516217	1470	1489	ventral hippocampus	T023	C0019564
27516217	1548	1559	hippocampal	T023	C0019564
27516217	1583	1596	shape changes	T033	C1562006
27516217	1598	1614	Chronic exposure	T033	C0743284
27516217	1625	1628	HAL	T109,T121	C0018546
27516217	1632	1635	OLZ	T109,T121	C0171023
27516217	1682	1685	rat	T015	C0034693
27516217	1686	1703	hippocampal shape	T023	C0175202